Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients

Transplant International

Volumn 18, Issue 1, 2005, Pages 29-35

  Miriuka, Santiago G ^a   Langman, Loralie J ^a,b   Evrovski, Jovan ^a,c   Miner, Steven E S ^a   D'Mello, Nisha ^a   Delgado, Diego H ^a   Wong, Betty Y L ^e   Ross, Heather J ^a   Cole, David E C ^a,c,d,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b BC Biomedical Laboratories Ltd   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f NONE   (Canada)

Author keywords

Cobalamin; Folate; Heart transplantation; Homocysteine; Methionine synthase reductase; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); COBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; 5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; FERREDOXIN NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE REDUCTASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PRIMER DNA;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; GENOTYPE; HEART GRAFT; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; BLOOD; GENETIC PREDISPOSITION; GENETICS; HEART TRANSPLANTATION; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RETROSPECTIVE STUDY;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADULT; BASE SEQUENCE; DNA PRIMERS; FERREDOXIN-NADP REDUCTASE; GENETIC PREDISPOSITION TO DISEASE; HEART TRANSPLANTATION; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 14944380707     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00021.x     Document Type: Article

References (28)

1. Marshall SE, Welsh KI. The role of cytokine polymorphisms in rejection after solid organ transplantation. Genes Immun 2001; 2: 297.
2. Miriuka SG, Delgado DH, Cole DEC, Rao V, Ross HJ. Hyperhomocysteinemia in heart transplantation: from bench to bedside. J Heart Lung Transplant 2003; 22: 1069.
3. Cole DE, Ross HJ, Evrovski J, et al. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 1998; 44: 2307.
4. Gupta A, Moustapha A, Jacobsen DW, et al. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998; 65: 544.
5. Ambrosi P, Garcon D, Riberi A, et al. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis 1998; 138: 347.
6. Miner SE, Cole DE, Evrovski J, Verma A, Daly PA, Ross HJ. Hyperhomocysteinemia and transplant coronary artery disease in cardiac transplant recipients. Clin Transplant 2001; 15: 258.
7. Langman LJ, Cole DE. Homocysteine. Crit Rev Clin Lab Sci 1999; 36: 365.
8. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost 2000; 26: 255.
9. Pethig K, Hoffmann A, Heublein B, Timke A, Gross G, Haverich A. Cardiac allograft vascular disease after orthotopic heart transplantation: methylenetetrahydrofolate reductase gene polymorphism C677T does not account for rapidly progressive forms. Transplantation 2000; 69: 442.
10. Potena L, Grigioni F, Viggiani M, et al. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C → T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. J Heart Lung Transplant 2001; 20: 1245.
11. Forrat R, Ferrera R, Boissonnat P, et al. High prevalence of thromoembolic complications in heart transplant recipients. Which preventive strategy? Transplantation 1996; 61: 757.
12. Labarrere CA. Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation. Curr Opin Cardiol 1999; 14: 133.
13. Ray JG, Langman LJ, Vermeulen MJ, Evrovski J, Yeo EL, Cole DE. Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women. Curr Control Trials Cardiovasc Med 2001; 2: 141.
14. Cole DE, Lehotay DC, Evrovski J. Simplified simultaneous assay of total plasma homocysteine and methionine by HPLC and pulsed integrated amperometry. Clin Chem 1998; 44: 188.
15. Miriuka SG, Langman LJ, Keren ES, et al. Effects of folic acid fortification and multivitamin therapy on homocysteine and vitamin B12 status in cardiac transplant patients. J Heart Lung Transplant 2004; 23: 405.
16. Ray JG, Vermeulen MJ, Boss SC, Cole DE. Declining rate of folate insufficiency among adults following increased folic acid food fortification in Canada. Can J Public Health 2002; 93: 249.
17. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111.
18. Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999; 67: 317.
19. Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867.
20. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042.
21. Geisel J, Zimbelmann I, Schorr H, et al. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 2001; 39: 698.
22. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195.
23. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1.
24. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 2000; 7: 197.
25. Rady PL, Szucs S, Grady J, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002; 107: 162.
26. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023.
27. Yates Z, Lucock M. Methionine synthase polymorphism A2756G is associated with susceptibility for thromboembolic events and altered B vitamin/thiol metabolism. Haematologica 2002; 87: 751.
28. Rozen R. Molecular biology of methylenetetrahydrofolate reductase (MTHFR): interrelationship with folic acid homocysteine and vascular disease. In: Robinson K, ed. Homocysteine and Vascular Disease. The Netherlands: Kluwer Academic Publisher, 2000: 271-289.